31 March 2025

Futura Medical plc

Board Appointment

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon^®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to announce the appointment of Harmesh Suniara to the Board as a Non-executive Director, with immediate effect

Harmesh has over 17 years' experience of working in investment management, with a particular focus on UK small and mid-cap equities. Since 2017 he has worked as a Portfolio Manager at Lombard Odier Asset Management (Europe) Limited, and from 2007, he was an Investment Manager at Henderson Volantis Capital and Gartmore Investment Management.

Funds or accounts managed on a discretionary basis by Lombard Odier Asset Management (Europe) Limited  hold in aggregate 86,781,198 ordinary shares of Futura Medical, representing 28.56% of Futura Medical's issued share capital.

Jeff Needham, Chairman of Futura, commented:

"I am delighted to welcome Harmesh to the Board of Futura.  We look forward to working with him as we continue our journey of meeting the unmet demand for sexual health products and take advantages of the opportunities available to us."

The following disclosures in relation to the appointment of Harmesh Kumar Suniara, aged 54, are required pursuant to Schedule 2(g) of the AIM Rules for Companies:

Harmesh Suniara was a Director at Actual Experience Plc, which entered administration on 14 November 2023.

No further information is required to be disclosed pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Contacts:

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon^® and products WSD4000 and Eroxon^® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon^®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon^® has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.